InsiderDB

Lobbying disclosures · Lobbying report

LLY: third_quarter 2026 lobbying report

General Healthcare issues, including drug accessibility, importation and innovation policies.

Follow LLY
Became public
Oct 20, 2026, 8:13 PM EDT
Event / period date
Not stated
Collected
Nov 12, 2026, 12:18 AM EST

Why this is connected

Legal-name match: ELI LILLY AND COMPANY is ELI LILLY & Co (https://www.sec.gov/Archives/edgar/data/59478/), differing only in punctuation, "the" or suffix spelling (Corp/Corporation).

Reported lobbying amounts

Income: $50,000.00

These are different reporting measures. They are not added together or treated as spending on one particular bill.

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/daa9abb1-089e-429b-9f7d-21a31663c2a4/","filing_uuid":"daa9abb1-089e-429b-9f7d-21a31663c2a4","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/daa9abb1-089e-429b-9f7d-21a31663c2a4/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Jay Engleson","dt_posted":"2026-10-20T20:13:54-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"750 9th St NW, Suite 650","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":65191,"url":"https://lda.gov/api/v1/registrants/65191/","house_registrant_id":35579,"name":"VENN STRATEGIES","description":"A political and public affairs consulting firm.","address_1":"750 9th St NW, Suite 650","address_2":null,"address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JAY ENGLESON","contact_telephone":"+1 301-509-9933","dt_updated":"2026-08-29T15:03:26.607563-04:00"},"client":{"id":162695,"url":"https://lda.gov/api/v1/clients/162695/","client_id":366,"name":"ELI LILLY AND COMPANY","general_description":"Pharmaceutical company","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2002-07-23"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"General Healthcare issues, including drug accessibility, importation and innovation policies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64837,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"SPIRA","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Congressional trading in LLY

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.